Skip to main content
Top
Published in: Neurological Sciences 6/2014

01-06-2014 | Original Article

Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson’s disease

Authors: Nadella Kumudini, Addepally Uma, Shaik Mohammad Naushad, Rukmini Mridula, Rupam Borgohain, Vijay Kumar Kutala

Published in: Neurological Sciences | Issue 6/2014

Login to get access

Abstract

The vulnerability of dopaminergic neurons to environmental exposures in sporadic Parkinson’s disease (PD) has been attributed to altered detoxification by xenobiotic metabolizing genes. Hence, we investigated the influence of genetic polymorphisms in xenobiotic metabolic pathway (CYP1A1 m1, CYP1A1 m2, CYP1A1 m4, COMT p.H108L, GSTT1, and GSTM1) on the susceptibility to PD. We used PCR–RFLP for CYP1A1 and COMT genotyping; multiplex-PCR for GSTT1 and GSTM1 deletion analysis; and spectrophotometric methods to evaluate the oxidative stress markers. Results showed association of CYP1A1 m1 (OR: 2.38, 95 % CI: 1.76–3.22) and COMT p.H108L (OR: 2.08 95 % CI: 1.56–2.77) polymorphisms with risk for PD. Male patients carrying combination of COMT p.H108L and CYP1A1 m1 variant alleles showed an early onset of the disease. There was a significant increase in oxidative stress makers such as malondialdehyde and protein carbonyls; and decrease in glutathione levels in PD cases compared to controls (P < 0.05). To conclude, CYP1A1 m1, COMT p.H108L polymorphisms were associated with PD risk, and sexual dimorphism was observed in these associations.
Literature
1.
2.
go back to reference Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157(11):1015–1022CrossRef Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157(11):1015–1022CrossRef
3.
go back to reference Warner TT, Schapira AH (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(Suppl 3):16–23CrossRef Warner TT, Schapira AH (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(Suppl 3):16–23CrossRef
4.
go back to reference Kurtz JF (1992) An overview of epidemiology of Parkinsonism. In: Hefti F, Weiner WJ (eds) Progress in Parkinson’s disease research. Mount Kisw Futura Publishing, New York, pp 119–169 Kurtz JF (1992) An overview of epidemiology of Parkinsonism. In: Hefti F, Weiner WJ (eds) Progress in Parkinson’s disease research. Mount Kisw Futura Publishing, New York, pp 119–169
5.
go back to reference Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 5:165–176PubMedCrossRef Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 5:165–176PubMedCrossRef
6.
go back to reference Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47(6 Suppl 3):161–170CrossRef Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47(6 Suppl 3):161–170CrossRef
7.
go back to reference Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269PubMedCrossRef Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269PubMedCrossRef
8.
go back to reference Jakoby WB, Ziegler DM (1990) The enzymes of detoxication. J Biol Chem 265(34):20715–20718PubMed Jakoby WB, Ziegler DM (1990) The enzymes of detoxication. J Biol Chem 265(34):20715–20718PubMed
9.
go back to reference Smith CA, Smith G, Wolf CR (1994) Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A(13):1921–1935PubMedCrossRef Smith CA, Smith G, Wolf CR (1994) Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A(13):1921–1935PubMedCrossRef
10.
go back to reference Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25–28PubMedCentralPubMed Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25–28PubMedCentralPubMed
11.
go back to reference Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I (1996) Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson’s disease. J Neural Transm 103:843–849PubMedCrossRef Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I (1996) Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson’s disease. J Neural Transm 103:843–849PubMedCrossRef
12.
go back to reference Stroombergen MC, Waring RH (1999) Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum Exp Toxicol 18:141–145PubMedCrossRef Stroombergen MC, Waring RH (1999) Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum Exp Toxicol 18:141–145PubMedCrossRef
13.
go back to reference Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Soderkvist P, Felice A, Geoparkinson Study Group (2007) Gene-environment interactions in parkinsonism and Parkinson’s disease: the geoparkinson study. Occup Environ Med 64:673–680PubMedCentralPubMedCrossRef Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Soderkvist P, Felice A, Geoparkinson Study Group (2007) Gene-environment interactions in parkinsonism and Parkinson’s disease: the geoparkinson study. Occup Environ Med 64:673–680PubMedCentralPubMedCrossRef
14.
go back to reference Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier DA (1997) High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson’s disease. Neurosci Lett 221(2–3):202–204PubMedCrossRef Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier DA (1997) High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson’s disease. Neurosci Lett 221(2–3):202–204PubMedCrossRef
15.
go back to reference Punia S, Das M, Behari M, Dihana M, Govindappa ST, Muthane UB, Thelma BK, Juyal RC (2011) Leads from xenobiotic metabolism genes for Parkinson’s disease among north Indians. Pharmacogenet Genomics 21(12):790–797PubMedCrossRef Punia S, Das M, Behari M, Dihana M, Govindappa ST, Muthane UB, Thelma BK, Juyal RC (2011) Leads from xenobiotic metabolism genes for Parkinson’s disease among north Indians. Pharmacogenet Genomics 21(12):790–797PubMedCrossRef
16.
go back to reference Placer ZA, Crushman LL, Johnson BC (1966) Estimation of products of lipid peroxidation (malonylaldehyde) in biochemical systems. Anal Biochem 16(2):359–364PubMedCrossRef Placer ZA, Crushman LL, Johnson BC (1966) Estimation of products of lipid peroxidation (malonylaldehyde) in biochemical systems. Anal Biochem 16(2):359–364PubMedCrossRef
17.
go back to reference Rajesh M, Sulochana KN, Coral K, Punitham R, Biswas J, Babu K, Ramakrishnan S (2004) Determination of carbonyl group content in plasma proteins as a useful marker to assess impairment in antioxidant defense in patients with Eales’ disease. Indian J Ophthalmol 52(2):139–144PubMed Rajesh M, Sulochana KN, Coral K, Punitham R, Biswas J, Babu K, Ramakrishnan S (2004) Determination of carbonyl group content in plasma proteins as a useful marker to assess impairment in antioxidant defense in patients with Eales’ disease. Indian J Ophthalmol 52(2):139–144PubMed
19.
go back to reference Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW (2006) Elevated levels of oxidized cholesterol metabolites in lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2:249–253PubMedCrossRef Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW (2006) Elevated levels of oxidized cholesterol metabolites in lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2:249–253PubMedCrossRef
20.
go back to reference Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res 85:919–934PubMedCrossRef Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res 85:919–934PubMedCrossRef
21.
go back to reference Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson’s disease: is this the elephant in the room? Biomed Pharmacother 62:236–249PubMedCrossRef Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson’s disease: is this the elephant in the room? Biomed Pharmacother 62:236–249PubMedCrossRef
22.
go back to reference Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53:26–36CrossRef Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53:26–36CrossRef
23.
go back to reference Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33(3):305–310PubMedCrossRef Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33(3):305–310PubMedCrossRef
24.
go back to reference Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM et al (1996) Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 20(7):1159–1170PubMedCrossRef Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM et al (1996) Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 20(7):1159–1170PubMedCrossRef
25.
go back to reference Venkateshappa C, Harish G, Mythri RB, Mahadevran A, Barath MMS, Shankar SK (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implication for Parkinson’ disease. Neurochem Res 37(2):358–369PubMedCrossRef Venkateshappa C, Harish G, Mythri RB, Mahadevran A, Barath MMS, Shankar SK (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implication for Parkinson’ disease. Neurochem Res 37(2):358–369PubMedCrossRef
26.
go back to reference Wang J, Liu Z, Chen B (2000) Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson’s disease. Zhonghua Yi Xue Za Zhi 80(8):585–587PubMed Wang J, Liu Z, Chen B (2000) Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson’s disease. Zhonghua Yi Xue Za Zhi 80(8):585–587PubMed
27.
go back to reference Chan DK, Mellick GD, Buchanan DD, Hung WT, Ng PW, Woo J, Kay R (2002) Lack of association between CYP1A1 polymorphism and Parkinson’s disease in a Chinese population. J Neural Transm 109(1):35–39PubMedCrossRef Chan DK, Mellick GD, Buchanan DD, Hung WT, Ng PW, Woo J, Kay R (2002) Lack of association between CYP1A1 polymorphism and Parkinson’s disease in a Chinese population. J Neural Transm 109(1):35–39PubMedCrossRef
28.
go back to reference Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Fukuoka Kinki Parkinson’s Disease Study Group (2011) Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson’s disease in a Japanese population. BMC Neurol 11:89PubMedCentralPubMedCrossRef Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Fukuoka Kinki Parkinson’s Disease Study Group (2011) Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson’s disease in a Japanese population. BMC Neurol 11:89PubMedCentralPubMedCrossRef
29.
go back to reference Lechun L, Yu S, Pengling H, Changqi H (2013) The COMT Val158Met polymorphism as an associated risk factor for Parkinson’s disease in Asian rather than Caucasian populations. Neurol India 61(1):12–16PubMedCrossRef Lechun L, Yu S, Pengling H, Changqi H (2013) The COMT Val158Met polymorphism as an associated risk factor for Parkinson’s disease in Asian rather than Caucasian populations. Neurol India 61(1):12–16PubMedCrossRef
30.
go back to reference de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ (2012) Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord 27(1):132–135PubMedCrossRef de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ (2012) Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord 27(1):132–135PubMedCrossRef
31.
go back to reference Klebe S, Golmard JL, Nalls MA, Saad M, Singleton AB, Bras JM, Hardy J, Simon-Sanchez J, Heutink P, Kuhlenbäumer G, Charfi R, Klein C, Hagenah J, Gasser T, Wurster I, Lesage S, Lorenz D, Deuschl G, Durif F, Pollak P, Damier P, Tison F, Durr A, Amouyel P, Lambert JC, Tzourio C, Maubaret C, Charbonnier-Beaupel F, Tahiri K, Vidailhet M, Martinez M, Brice A, Corvol JC, French Parkinson’s Disease Genetics Study Group, International Parkinson’s Disease Genomics Consortium (IPDGC) (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 84(6):666–673PubMedCentralPubMedCrossRef Klebe S, Golmard JL, Nalls MA, Saad M, Singleton AB, Bras JM, Hardy J, Simon-Sanchez J, Heutink P, Kuhlenbäumer G, Charfi R, Klein C, Hagenah J, Gasser T, Wurster I, Lesage S, Lorenz D, Deuschl G, Durif F, Pollak P, Damier P, Tison F, Durr A, Amouyel P, Lambert JC, Tzourio C, Maubaret C, Charbonnier-Beaupel F, Tahiri K, Vidailhet M, Martinez M, Brice A, Corvol JC, French Parkinson’s Disease Genetics Study Group, International Parkinson’s Disease Genomics Consortium (IPDGC) (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 84(6):666–673PubMedCentralPubMedCrossRef
32.
go back to reference Wahner AD, Glatt ChE, Bronstein JM, Ritz B (2007) Glutathione S-transferase mu, omega, pi and theta class variants and smoking in Parkinson’s disease. Neurosci Lett 413(3):274–278PubMedCentralPubMedCrossRef Wahner AD, Glatt ChE, Bronstein JM, Ritz B (2007) Glutathione S-transferase mu, omega, pi and theta class variants and smoking in Parkinson’s disease. Neurosci Lett 413(3):274–278PubMedCentralPubMedCrossRef
33.
go back to reference Kelada SN, Stapleton PL, Farin FM, Bammler TK, Eaton DL, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT Jr, Checkoway H (2003) Glutathione S-transferases M1, T1 and P1 polymorphisms and Parkinson’s disease. Neurosci Lett 337(1):5–8PubMedCrossRef Kelada SN, Stapleton PL, Farin FM, Bammler TK, Eaton DL, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT Jr, Checkoway H (2003) Glutathione S-transferases M1, T1 and P1 polymorphisms and Parkinson’s disease. Neurosci Lett 337(1):5–8PubMedCrossRef
34.
go back to reference Perez-Pastene C, Graumann R, Diaz-Grez F, Miranda M, Venegas P, Godoy OT, Layson L, Villagra R, Matala JM, Herrera L, Segura-Aguilar J (2007) Association of GST M1 oxidative changes and possible effects of polymorphism of antioxidant enzymes in neurodegenerative disease null polymorphism with Parkinson’s disease in a Chilean population with strong Amerindian genetic component. Neurosci Lett 418(2):181–185PubMedCrossRef Perez-Pastene C, Graumann R, Diaz-Grez F, Miranda M, Venegas P, Godoy OT, Layson L, Villagra R, Matala JM, Herrera L, Segura-Aguilar J (2007) Association of GST M1 oxidative changes and possible effects of polymorphism of antioxidant enzymes in neurodegenerative disease null polymorphism with Parkinson’s disease in a Chilean population with strong Amerindian genetic component. Neurosci Lett 418(2):181–185PubMedCrossRef
35.
go back to reference Stroombergen MC, Waring RH (1999) Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum Exp Toxicol 18(3):141–145PubMedCrossRef Stroombergen MC, Waring RH (1999) Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum Exp Toxicol 18(3):141–145PubMedCrossRef
36.
go back to reference Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG (1998) Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet 352:1344–1346PubMedCrossRef Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG (1998) Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet 352:1344–1346PubMedCrossRef
37.
go back to reference Mellick GD (2006) CYP450, genetics and Parkinson’s disease: gene x environment interactions hold the key. J Neural Transm Suppl 70:159–165PubMedCrossRef Mellick GD (2006) CYP450, genetics and Parkinson’s disease: gene x environment interactions hold the key. J Neural Transm Suppl 70:159–165PubMedCrossRef
Metadata
Title
Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson’s disease
Authors
Nadella Kumudini
Addepally Uma
Shaik Mohammad Naushad
Rukmini Mridula
Rupam Borgohain
Vijay Kumar Kutala
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 6/2014
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-013-1622-3

Other articles of this Issue 6/2014

Neurological Sciences 6/2014 Go to the issue